drugset / Trial / NCT03588494
Endostar in Combination With Chemoradiotherapy in Patient With Advanced Non-small Cell Lung Cancer
Phase 2/3
Unknown
318 enrolled
Affiliated Hospital of North Sichuan Medical College
Jiangsu Simcere Pharmaceutical Co., Ltd. · collab
RandomizedParallel-groupTriple-blindTreatment
Summary
To investigate the safety and efficacy recombinant human endostatin(endostar) durative transfusion combined with cocurrent chemoradiotherapy in advanced non-small cell lung cancer(NSCLC).
Timeline
- Start
- 2018-08-01
- Primary completion
- 2019-09-01
- Completion
- 2021-09-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Endostar | Protein / enzyme biologic | 15 mg/m2 | — |
| Background | Cisplatin | Other / unclassified | 50 mg/m2 | — |
| Background | Etoposide | Small molecule | 50 mg/m2 | — |
Indications
No indication recorded.